Changes in apolipoprotein B100-containing lipoprotein metabolism due to an estrogen plus progestin oral contraceptive: A stable isotope kinetic study

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 5, 2010, Pages 2140-2146

  Duvillard, Laurence ^a,b   Dautin, Guillaume ^a   Florentin, Emmanuel ^a,b   Petit, Jean Michel ^a,c   Gambert, Philippe ^a,b   Vergès, Bruno ^a,c  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; CARBON 13; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; GESTAGEN; GESTODENE; INTERMEDIATE DENSITY LIPOPROTEIN; LEUCINE; LOW DENSITY LIPOPROTEIN; ORAL CONTRACEPTIVE AGENT; VERY LOW DENSITY LIPOPROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREGNANE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CATABOLISM; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; ISOTOPE ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; NORMAL HUMAN; PRIORITY JOURNAL; ADOLESCENT; BLOOD; DRUG EFFECT; KINETICS; METABOLISM;

ADOLESCENT; ADULT; APOLIPOPROTEIN B-100; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; KINETICS; LEUCINE; LIPOPROTEINS, LDL; NORPREGNENES; TRIGLYCERIDES; YOUNG ADULT;

EID: 77952756795     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2480     Document Type: Article

References (33)

1. Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H 1998 Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception 58:83-91
2. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V 1990 The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375-1381
3. Fotherby K 1995 Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception 51:3-12
4. Winkler UH, Sudik R 2009 The effects of two monophasic oral contraceptives containing 30mcg of ethinyl estradiol and either 2mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception 79:15-23
5. Kauppinen-Mäkelin R, Kuusi T, Ylikorkala O, Tikkanen MJ 1992 Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. Clin Endocrinol (Oxf) 36:203-209
6. Applebaum DM, Goldberg AP, Pykälistö OJ, Brunzell JD, Hazzard WR 1977 Effect of estrogen on post-heparin lipolytic activity. Selective decline in hepatic triglyceride lipase. J Clin Invest 59:601-608
7. Parini P, Angelin B, Rudling M 1997 Importance of estrogen receptors in hepatic LDL receptor regulation. Arterioscler Thromb Vasc Biol 17:1800-1805
8. Semenkovich CF, Ostlund Jr RE 1987 Estrogens induce low-density lipoprotein receptor activity and decrease intracellular cholesterol in human hepatoma cell line Hep G2. Biochemistry 26:4987-4992
9. Campos H, Walsh BW, Judge H, Sacks FM 1997 Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab 82:3955-3963
10. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM 1991 Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196-1204
11. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer Jr HB, Levy RI 1983 The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57:262-267
12. Walsh BW, Sacks FM 1993 Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest 91:2126-2132 (Pubitemid 23141487)
13. Duvillard L, Florentin E, Lalanne-Mistrich ML, Petit JM, Baillot-Rudoni S, Brun-Pacaud A, Brun JM, Gambert P, Vergès B 2005 Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men. Diabetologia 48:1366-1372
14. Duvillard L, Pont F, Florentin E, Gambert P, Vergès B 2000 Significant improvement of apoB-containing lipoprotein metabolism by insulin treatment in NIDDM patients. Diabetologia 43:27-35
15. Petit JM, Duong M, Florentin E, Duvillard L, Chavanet P, Brun JM, Portier H, Gambert P, Verges B 2003 Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study. J Lipid Res 44:1692-1697
16. Lundholm L, Zang H, Hirschberg AL, Gustafsson JA, Arner P, Dahlman-Wright K 2008 Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. Fertil Steril 90:44-48
17. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F, Andò S 2005 Estrogen receptor β binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells. Clin Cancer Res 11:6139-6147
18. Byrne CD, Wang TW, Hales CN 1992 Control of Hep G2-cell triacylglycerol and apolipoproteinBsynthesis and secretion by polyunsaturated non-esterified fatty acids and insulin. Biochem J 288:101-107
19. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G 1995 Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158-166
20. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE 2006 Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. J Biol Chem 281:2654-2660
21. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y 2001 PPAR γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099
22. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295
23. Muoio DM, Seefeld K, Witters LA, Coleman RA 1999 AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 338:783-791
24. Kunnari A, Santaniemi M, Jokela M, Karjalainen AH, Heikkinen J, Ukkola O, Kesäniemi YA 2008 Estrogen replacement therapy decreases plasma adiponectin but not resistin in postmenopausal women. Metabolism 57:1509-1515
25. Pont F, Duvillard L, Florentin E, Gambert P, Vergès B 2002 Early kinetic abnormalities of apoB-containing lipoproteins in insulinresistant women with abdominal obesity. Arterioscler Thromb Vasc Biol 22:1726-1732
26. Gaw A, Packard CJ, Lindsay GM, Griffin BA, Caslake MJ, Lorimer AR, Shepherd J 1995 Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res 36:158-171
27. Pietzsch J, Lattke P, Julius U 2000 Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies. Arterioscler Thromb Vasc Biol 20:E63-E67
28. Viens L, Lagrost L 1997 Effect of lipid transfer activity and triglyceride hydrolysis on apolipoprotein B immunoreactivity in modified low density lipoproteins. J Lipid Res 38:1129-1138 (Pubitemid 27281808)
29. Aviram M, Bierman EL, Chait A 1988 Modification of low density lipoprotein by lipoprotein lipase or hepatic lipase induces enhanced uptake and cholesterol accumulation in cells. J Biol Chem 263:15416-15422
30. Tilly-Kiesi M, Syvänne M, Kuusi T, Lahdenperä S, Taskinen MR 1992 Abnormalities of low density lipoproteins in normolipidemic type II diabetic and nondiabetic patients with coronary artery disease. J Lipid Res 33:333-342
31. Shufelt CL, Bairey Merz CN 2009 Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 53:221-231
32. Magkos F, Patterson BW, Mittendorfer B 2007 Reproducibility of stable isotope-labeled tracer measures of VLDL-triglyceride and VLDL-apolipoprotein B-100 kinetics. J Lipid Res 48:1204-1211
33. Pont F, Duvillard L, Maugeais C, Athias A, Perségol L, Gambert P, Vergès B 1997 Isotope ratio mass spectrometry, compared with conventional mass spectrometry in kinetic studies at low and high enrichment levels: application to lipoprotein kinetics. Anal Biochem 248:277-287 (Pubitemid 27233165)